Emerging Markets Earnings Roundup: Roche, Lilly, Bristol Myers Squibb (Part 2)
This article was originally published in PharmAsia News
Executive Summary
China remains the star in emerging markets, with Roche reporting 26% growth in China for pharma and 19% in diagnostics, and Eli Lilly & Co. reporting 18% growth in China. Bristol-Myers Squibb Co. had little to report on EMs, but it signed a manufacturing agreement with South Korea’s Samsung BioLogics for an undisclosed cancer drug.